OXPHOS, Pyrimidine Nucleotides, and Alzheimer's Disease: A Pharmacogenomics Approach

Journal of Alzheimer's Disease

Volumn 42, Issue 1, 2014, Pages 87-96

  Pesini, Alba ^a   Iglesias, Eldris ^a   Garrido, Nuria ^a   Bayona Bafaluy, M Pilar ^a   Montoya, Julio ^a   Ruiz Pesini, Eduardo ^a  

^a UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

Alzheimer's disease; coenzyme Q10; de novo pyrimidine biosynthesis; dihydroorotate dehydrogenase; mitochondrial DNA; oxidative phosphorylation

Indexed keywords

AMYLOID BETA PROTEIN; MITOCHONDRIAL DNA; PYRIMIDINE NUCLEOTIDE; NOOTROPIC AGENT;

ALZHEIMER DISEASE; ARTICLE; HAPLOTYPE; HUMAN; INTRACELLULAR SIGNALING; NERVE CELL MEMBRANE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PATHOGENICITY; PHARMACOGENOMICS; PRIORITY JOURNAL; PYRIMIDINE SYNTHESIS; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; GENETICS; METABOLISM; NERVE CELL; PHARMACOGENETICS; PROCEDURES;

ALZHEIMER DISEASE; ANIMALS; DNA, MITOCHONDRIAL; HUMANS; NEURONS; NOOTROPIC AGENTS; OXIDATIVE PHOSPHORYLATION; PHARMACOGENETICS; PYRIMIDINE NUCLEOTIDES;

EID: 84925665795     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140384     Document Type: Article

References (114)

1. Hardy JA, Higgins GA (1992) Alzheimer's disease: The amyloid cascade hypothesis. Science 256, 184-185.
2. Hansson Petersen CA, Alikhani N, Behbahani H, Wiehager B, Pavlov PF, Alafuzoff I, Leinonen V, Ito A, Winblad B, Glaser E, AnkarcronaM(2008) The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci U S A 105, 13145-13150.
3. Hernandez-Zimbron LF, Luna-Munoz J, Mena R, Vazquez- Ramirez R, Kubli-Garfias C, Cribbs DH, Manoutcharian K, Gevorkian G (2012) Amyloid-beta peptide binds to cytochrome C oxidase subunit 1. PLoS One 7, e42344.
4. Rhein V, Baysang G, Rao S, Meier F, Bonert A, Muller- Spahn F, Eckert A (2009) Amyloid-beta leads to impaired cellular respiration, energy production and mitochondrial electron chain complex activities in human neuroblastoma cells. Cell Mol Neurobiol 29, 1063-1071.
5. Rhein V, Song X, Wiesner A, Ittner LM, Baysang G, Meier F, Ozmen L, Bluethmann H, Drose S, Brandt U, Savaskan E, Czech C, Gotz J, EckertA(2009) Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci U S A 106, 20057-20062.
6. ReitzC(2012) Alzheimer's disease and the amyloid cascade hypothesis: A critical review. Int J Alzheimers Dis 2012, 369808.
7. Swerdlow RH, Khan SM (2004) A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Med Hypotheses 63, 8-20.
8. Parker WD Jr, Filley CM, Parks JK (1990) Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 40, 1302-1303.
9. Swerdlow RH, Burns JM, Khan SM (2013) The Alzheimer's disease mitochondrial cascade hypothesis: Progress and perspectives. Biochim Biophys Acta. doi:10.1016/j.bbadis.2013.09.010, Sep 23. pii: S0925- 4439(13)00289-5. [Epub ahead of print] PMID: 24071439.
10. Gabuzda D, Busciglio J, Chen LB, Matsudaira P, Yankner BA (1994) Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem 269, 13623-13628.
11. Gasparini L, Racchi M, Benussi L, Curti D, Binetti G, Bianchetti A, Trabucchi M, Govoni S (1997) Effect of energy shortage and oxidative stress on amyloid precursor protein metabolism in COS cells. Neurosci Lett 231, 113-117.
12. Webster MT, Pearce BR, Bowen DM, Francis PT (1998) The effects of perturbed energy metabolism on the processing of amyloid precursor protein in PC12 cells. J Neural Transm 105, 839-853.
13. Hedin HL, Eriksson S, Fowler CJ (2000) Rapid inhibition by sodium azide of the phosphoinositide-mediated calcium response to serotonin stimulation in human platelets: Preservation in Alzheimer's disease. Biochem Biophys Res Commun 274, 472-476.
14. Busciglio J, Pelsman A, Wong C, Pigino G, Yuan M, Mori H, Yankner BA (2002) Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron 33, 677-688.
15. Webster NJ, Green KN, Peers C, Vaughan PF (2002) Altered processing of amyloid precursor protein in the human neuroblastoma SH-SY5Y by chronic hypoxia. J Neurochem 83, 1262-1271.
16. Webster NJ, Green KN, Settle VJ, Peers C, Vaughan PF (2004) Altered processing of the amyloid precursor protein and decreased expression of ADAM 10 by chronic hypoxia in SH-SY5Y: No role for the stress-activated JNK and p38 signalling pathways. Brain Res Mol Brain Res 130, 161-169.
17. Henriques AG, Domingues SC, Fardilha M, da Cruz e Silva EF, da Cruz e Silva OA (2005) Sodium azide and 2-deoxy- D-glucose-induced cellular stress affects phosphorylationdependent AbetaPP processing. J Alzheimers Dis 7, 201-212; discussion 255-262.
18. Velliquette RA, O'Connor T, Vassar R (2005) Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: Possible early events in Alzheimer's disease pathogenesis. J Neurosci 25, 10874-10883.
19. Xiong K, Cai H, Luo XG, Struble RG, Clough RW, Yan XX (2007) Mitochondrial respiratory inhibition and oxidative stress elevate beta-secretase (BACE1) proteins and activity in vivo in the rat retina. Exp Brain Res 181, 435-446.
20. Lopez-Martin JM, Salviati L, Trevisson E, Montini G, DiMauro S, Quinzii C, Hirano M, Rodriguez-Hernandez A, Cordero MD, Sanchez-Alcazar JA, Santos-Ocana C, Navas P (2007) Missense mutation of the COQ2 gene causes defects of bioenergetics and de novo pyrimidine synthesis. Hum Mol Genet 16, 1091-1097.
21. Loffler M (1992) A cytokinetic approach to determine the range of O2-dependence of pyrimidine(deoxy)nucleotide biosynthesis relevant for cell proliferation. Cell Prolif 25, 169-179.
22. King MP, Attardi G (1989) Human cells lacking mtDNA: Repopulation with exogenous mitochondria by complementation. Science 246, 500-503.
23. Gattermann N, Dadak M, Hofhaus G, Wulfert M, Berneburg M, Loeffler ML, Simmonds HA (2004) Severe impairment of nucleotide synthesis through inhibition of mitochondrial respiration. Nucleosides Nucleotides Nucleic Acids 23, 1275-1279.
24. Khutornenko AA, Roudko VV, Chernyak BV, Vartapetian AB, Chumakov PM, Evstafieva AG (2010) Pyrimidine biosynthesis links mitochondrial respiration to the p53 pathway. Proc Natl Acad Sci U S A 107, 12828-12833.
25. Beuneu C, Auger R, Loffler M, Guissani A, Lemaire G, Lepoivre M (2000) Indirect inhibition of mitochondrial dihydroorotate dehydrogenase activity by nitric oxide. Free Radic Biol Med 28, 1206-1213.
26. Garcia RA, Liu L, Hu Z, Gonzalez A, von Borstel RW, Saydoff JA(2005) Severe cytochrome c oxidase inhibition in vivo does not induce a pyrimidine deficiency; neuroprotective action of oral uridine prodrug PN401 requires supraphysiological levels of uridine. Brain Res 1066, 164-171.
27. Saydoff JA, Olariu A, Sheng J, Hu Z, Li Q, Garcia R, Pei J, Sun GY, von Borstel R (2013) Uridine prodrug improves memory in Tg2576 and TAPP mice and reduces pathological factors associated with Alzheimer's disease in related models. J Alzheimers Dis 36, 637-657.
28. Evans DR, Guy HI (2004) Mammalian pyrimidine biosynthesis: Fresh insights into an ancient pathway. J Biol Chem 279, 33035-33038.
29. Gerlach J, Loffler M, Schafer MK (2011) Gene expression of enzymes required for the de novo synthesis and degradation of pyrimidines in rat peripheral tissues and brain. Nucleosides Nucleotides Nucleic Acids 30, 1147-1154.
30. Schaefer Ch M, Schafer MK, Lofflerr M (2010) Regionspecific distribution of dihydroorotate dehydrogenase in the rat central nervous system points to pyrimidine de novo synthesis in neurons. Nucleosides Nucleotides Nucleic Acids 29, 476-481.
31. Pfenninger KH(2009) Plasma membrane expansion:Aneuron's Herculean task. Nat Rev Neurosci 10, 251-261.
32. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298, 789-791.
33. Yao JK, Wengenack TM, Curran GL, Poduslo JF (2009) Reduced membrane lipids in the cortex of Alzheimer's disease transgenic mice. Neurochem Res 34, 102-108.
34. Nitsch RM, Blusztajn JK, Pittas AG, Slack BE, Growdon JH, Wurtman RJ (1992) Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci U S A 89, 1671-1675.
35. Gottfries CG, Karlsson I, Svennerholm L (1996) Membrane components separate early-onset Alzheimer's disease from senile dementia of the Alzheimer type. Int Psychogeriatr 8, 365-372.
36. Pettegrew JW, Panchalingam K, Hamilton RL, McClure RJ (2001) Brain membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 26, 771-782.
37. Hatch GM, McClarty G (1996) Regulation of cardiolipin biosynthesis in H9c2 cardiac myoblasts by cytidine 5'- triphosphate. J Biol Chem 271, 25810-25816.
38. Ross BM, Moszczynska A, Blusztajn JK, Sherwin A, Lozano A, Kish SJ (1997) Phospholipid biosynthetic enzymes in human brain. Lipids 32, 351-358.
39. Ziabreva I, Campbell G, Rist J, Zambonin J, Rorbach J, Wydro MM, Lassmann H, Franklin RJ, Mahad D (2010) Injury and differentiation following inhibition of mitochondrial respiratory chain complex IV in rat oligodendrocytes. Glia 58, 1827-1837.
40. Farber SA, Slack BE, Blusztajn JK (2000) Acceleration of phosphatidylcholine synthesis and breakdown by inhibitors of mitochondrial function in neuronal cells: A model of the membrane defect of Alzheimer's disease. FASEB J 14, 2198-2206.
41. Brand MD (2000) Uncoupling to survive? The role of mitochondrial inefficiency in ageing. Exp Gerontol 35, 811-820.
42. Wasilewska-Sampaio AP, Silveira MS, Holub O, Goecking R, Gomes FC, Neto VM, Linden R, Ferreira ST, De Felice FG (2005) Neuritogenesis and neuronal differentiation promoted by 2,4-dinitrophenol, a novel anti-amyloidogenic compound. FASEB J 19, 1627-1636.
43. Freitas-Correa L, Lourenco MV, Acquarone M, da Costa RF, Galina A, Rehen SK, Ferreira ST (2013) 2,4-dinitrophenol induces neural differentiation of murine embryonic stem cells. Stem Cell Res 11, 1407-1416.
44. Lopez GC I, Agut J, Ortiz JA, Wurtman RJ (1992) Effects of orally administered cytidine 5'-diphosphate choline on brain phospholipid content. J Nutr Biochem 3, 313-315.
45. Knapp S, Wurtman RJ (1999) Enhancement of free fatty acid incorporation into phospholipids by choline plus cytidine. Brain Res 822, 52-59.
46. Silei V, Politi V, Lauro GM (2000) Uridine induces differentiation in human neuroblastoma cells via protein kinase C epsilon. J Neurosci Res 61, 206-211.
47. Wang CS, Lee RK (2000) Choline plus cytidine stimulate phospholipid production, and the expression and secretion of amyloid precursor protein in rat PC12 cells. Neurosci Lett 283, 25-28.
48. Pooler AM, Guez DH, Benedictus R, Wurtman RJ (2005) Uridine enhances neurite outgrowth in nerve growth factor-differentiated PC12 [corrected]. Neuroscience 134, 207-214.
49. Savci V, Wurtman RJ (1995) Effect of cytidine on membrane phospholipid synthesis in rat striatal slices. J Neurochem 64, 378-384.
50. Alberghina M, Viola M, Serra I, Mistretta A, Giuffrida AM (1981) Effect of CDP-choline on the biosynthesis of phospholipids in brain regions during hypoxic treatment. J Neurosci Res 6, 421-433.
51. Trovarelli G, de Medio GE, Dorman RV, Piccinin GL, Horrocks LA, PorcellatiG(1981) Effect of cytidine diphosphate choline (CDP-choline) on ischemia-induced alterations of brain lipid in the gerbil. Neurochem Res 6, 821-833.
52. Trovarelli G, Palmerini CA, Floridi A, Piccinin GL, De Medio GE (1987) Effect of cytidine on the modification of phospholipid metabolism induced by ischemia. Neurochem Res 12, 227-230.
53. Agut J, Lopez GC I, Ortiz JA, Wurtman RJ (1993) Oral cytidine 5'-diphosphate choline administration to rats increases brain phospholipid levels. Ann N Y Acad Sci 695, 318-320.
54. Lopez-Coviella I, Agut J, Savci V, Ortiz JA, Wurtman RJ (1995) Evidence that 5'-cytidinediphosphocholine can affect brain phospholipid composition by increasing choline and cytidine plasma levels. J Neurochem 65, 889-894.
55. Rao AM, Hatcher JF, Dempsey RJ (2000) Lipid alterations in transient forebrain ischemia: Possible newmechanisms of CDP-choline neuroprotection. J Neurochem 75, 2528-2535.
56. Adibhatla RM, Hatcher JF, Dempsey RJ (2001) Effects of citicoline on phospholipid and glutathione levels in transient cerebral ischemia. Stroke 32, 2376-2381.
57. Wang L, Pooler AM, Albrecht MA, Wurtman RJ (2005) Dietary uridine-5'-monophosphate supplementation increases potassium-evoked dopamine release and promotes neurite outgrowth in aged rats. J Mol Neurosci 27, 137-145.
58. Wurtman RJ, Ulus IH, Cansev M, Watkins CJ, Wang L, Marzloff G (2006) Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally. Brain Res 1088, 83-92.
59. Cansev M, Wurtman RJ (2007) Chronic administration of docosahexaenoic acid or eicosapentaenoic acid, but not arachidonic acid, alone or in combination with uridine, increases brain phosphatide and synaptic protein levels in gerbils. Neuroscience 148, 421-431.
60. Hurtado O, Cardenas A, Pradillo JM, Morales JR, Ortego F, Sobrino T, Castillo J, Moro MA, Lizasoain I (2007) A chronic treatment with CDP-choline improves functional recovery and increases neuronal plasticity after experimental stroke. Neurobiol Dis 26, 105-111.
61. Wurtman RJ, Cansev M, Sakamoto T, Ulus IH (2009) Administration of docosahexaenoic acid, uridine and choline increases levels of synaptic membranes and dendritic spines in rodent brain.World Rev Nutr Diet 99, 71-96.
62. Morel E, Chamoun Z, Lasiecka ZM, Chan RB, Williamson RL, Vetanovetz C, Dall'Armi C, Simoes S, Point Du Jour KS, McCabe BD, Small SA, Di Paolo G (2013) Phosphatidylinositol-3-phosphate regulates sorting and processing of amyloid precursor protein through the endosomal system. Nat Commun 4, 2250.
63. Stokes CE, Hawthorne JN (1987) Reduced phosphoinositide concentrations in anterior temporal cortex of Alzheimerdiseased brains. J Neurochem 48, 1018-1021.
64. Tyeryar KR, VongtauH O, Undieh AS(2008) Diverse antidepressants increase CDP-diacylglycerol production and phosphatidylinositide resynthesis in depression-relevant regions of the rat brain. BMC Neurosci 9, 12.
65. Aboukhatwa MA, Undieh AS (2010) Antidepressant stimulation of CDP-diacylglycerol synthesis does not require monoamine reuptake inhibition. BMC Neurosci 11, 10.
66. Dias WB, Hart GW (2007) O-GlcNAc modification in diabetes and Alzheimer's disease. Mol Biosyst 3, 766-772.
67. Kreppel LK, Hart GW (1999) Regulation of a cytosolic and nuclear O-GlcNAc transferase. Role of the tetratricopeptide repeats. J Biol Chem 274, 32015-32022.
68. Lefebvre T, Guinez C, Dehennaut V, Beseme-Dekeyser O, Morelle W, Michalski JC (2005) Does O-GlcNAc play a role in neurodegenerative diseases? Expert Rev Proteomics 2, 265-275.
69. Liu F, Shi J, Tanimukai H, Gu J, Grundke-Iqbal I, Iqbal K, Gong CX (2009) Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. Brain 132, 1820-1832.
70. Yuzwa SA, Shan X, Macauley MS, Clark T, Skorobogatko Y, Vosseller K, Vocadlo DJ (2012) Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat Chem Biol 8, 393-399.
71. Deng Y, Li B, Liu F, Iqbal K, Grundke-Iqbal I, Brandt R, Gong CX (2008) Regulation between O-GlcNAcylation and phosphorylation of neurofilament-M and their dysregulation in Alzheimer disease. FASEB J 22, 138-145.
72. Jacobsen KT, IverfeldtK(2011) O-GlcNAcylation increases non-amyloidogenic processing of the amyloid-beta precursor protein (APP). Biochem Biophys Res Commun 404, 882-886.
73. Broersen LM, Kuipers AA, Balvers M, vanWijk N, Savelkoul PJ, deWildeMC,van der Beek EM, SijbenJ W, Hageman RJ, Kamphuis PJ, Kiliaan AJ (2013) A specific multinutrient diet reduces Alzheimer-like pathology in young adult AbetaPPswe/PS1dE9 mice. J Alzheimers Dis 33, 177-190.
74. Cherry CL, Mobarok M, Wesselingh SL, Fain R, Weinstock S, Tachedjian G, Srivastava S, Tyssen DP, Glass JD, Hooker DJ (2010) Ubisol-Aqua: Coenzyme Q10 prevents antiretroviral toxic neuropathy in an in vitro model. Curr HIV Res 8, 232-239.
75. Li G, Jack CR, Yang XF, Yang ES (2008) Diet supplement CoQ10 delays brain atrophy in aged transgenic mice with mutations in the amyloid precursor protein: An in vivo volume MRI study. Biofactors 32, 169-178.
76. Dumont M, Kipiani K, Yu F, Wille E, Katz M, Calingasan NY, Gouras GK, Lin MT, Beal MF (2011) Coenzyme Q10 decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 27, 211-223.
77. Katoh S, Mitsui Y, Kitani K, Suzuki T (1997) Hyperoxia induces the differentiated neuronal phenotype of PC12 cells by producing reactive oxygen species. Biochem Biophys Res Commun 241, 347-351.
78. Gao B, Long Z, Zhao L, He G (2011) Effect of normobaric hyperoxia on behavioral deficits and neuropathology in Alzheimer's disease mouse model. J Alzheimers Dis 27, 317-326.
79. Sheng B, Wang X, Su B, Lee HG, Casadesus G, Perry G, Zhu X (2012) Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease. J Neurochem 120, 419-429.
80. Cerqueira FM, Laurindo FR, Kowaltowski AJ (2011) Mild mitochondrial uncoupling and calorie restriction increase fasting eNOS, akt and mitochondrial biogenesis. PLoS One 6, e18433.
81. Vaughan RA, Garcia-Smith R, Bisoffi M, Trujillo KA, Conn CA (2012) Effects of caffeine on metabolism and mitochondria biogenesis in rhabdomyosarcoma cells compared with 2,4-dinitrophenol. Nutr Metab Insights 5, 59-70.
82. Grundlingh J, Dargan PI, El-Zanfaly M, Wood DM (2011) 2,4-dinitrophenol (DNP): A weight loss agent with significant acute toxicity and risk of death. J Med Toxicol 7, 205-212.
83. Dasgupta B, Milbrandt J (2007) Resveratrol stimulatesAMP kinase activity in neurons. Proc Natl Acad Sci U S A 104, 7217-7222.
84. Porquet D, Casadesus G, Bayod S, Vicente A, Canudas AM, Vilaplana J, Pelegri C, Sanfeliu C, Camins A, Pallas M, del Valle J (2013) Dietary resveratrol prevents Alzheimer's markers and increases life span in SAMP8. Age (Dordr) 35, 1851-1865.
85. Miglio G, Rosa AC, Rattazzi L, Collino M, Lombardi G, Fantozzi R (2009) PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivationinduced neuronal cell loss. Neurochem Int 55, 496-504.
86. Strum JC, Shehee R, Virley D, Richardson J, Mattie M, Selley P, Ghosh S, Nock C, Saunders A, Roses A (2007) Rosiglitazone induces mitochondrial biogenesis in mouse brain. J Alzheimers Dis 11, 45-51.
87. Brodbeck J, Balestra ME, Saunders AM, Roses AD, Mahley RW, HuangY(2008) Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons. Proc Natl Acad Sci U S A 105, 1343-1346.
88. Landreth G, Jiang Q, Mandrekar S, Heneka M (2008) PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 5, 481-489.
89. Mosharrof AH, Petkov VD, Petkov VV (1987) Effects of meclofenoxate and citicholine on learning and memory in aged rats. Acta Physiol Pharmacol Bulg 13, 17-24.
90. Drago F, D'Agata V, Valerio C, Spadaro F, Raffaele R, Nardo L, Grassi M, Freni V (1990) Memory deficits of aged male rats can be improved by pyrimidine nucleosides and n-acetyl-glutamine. Clin Neuropharmacol 13, 290-296.
91. Alvarez XA, Sampedro C, Lozano R, Cacabelos R (1999) Citicoline protects hippocampal neurons against apoptosis induced by brain beta-amyloid deposits plus cerebral hypoperfusion in rats. Methods Find Exp Clin Pharmacol 21, 535-540.
92. Teather LA, Wurtman RJ (2003) Dietary cytidine (5')-diphosphocholine supplementation protects against development of memory deficits in aging rats. Prog Neuropsychopharmacol Biol Psychiatry 27, 711-717.
93. Teather LA, Wurtman RJ (2005) Dietary CDP-choline supplementation prevents memory impairment caused by impoverished environmental conditions in rats. Learn Mem 12, 39-43.
94. Teather LA, Wurtman RJ (2006) Chronic administration of UMP ameliorates the impairment of hippocampaldependent memory in impoverished rats. J Nutr 136, 2834-2837.
95. Holguin S, Martinez J, Chow C, Wurtman R (2008) Dietary uridine enhances the improvement in learning and memory produced by administering DHA to gerbils. FASEB J 22, 3938-3946.
96. Takasaki K, Uchida K, Fujikawa R, Nogami A, Nakamura K, Kawasaki C, Yamaguchi K, Morita M, Morishita K, Kubota K, Katsurabayashi S, Mishima K, Fujiwara M, Iwasaki K (2011) Neuroprotective effects of citidine-5- diphosphocholine on impaired spatial memory in a rat model of cerebrovascular dementia. J Pharmacol Sci 116, 232-237.
97. Spiers PA, Myers D, Hochanadel GS, Lieberman HR, Wurtman RJ (1996) Citicoline improves verbal memory in aging. Arch Neurol 53, 441-448.
98. Alvarez XA, Laredo M, Corzo D, Fernandez-Novoa L, Mouzo R, Perea JE, Daniele D, Cacabelos R (1997) Citicoline improves memory performance in elderly subjects. Methods Find Exp Clin Pharmacol 19, 201-210.
99. Alvarez XA, Mouzo R, Pichel V, Perez P, Laredo M, Fernandez-Novoa L, Corzo L, Zas R, Alcaraz M, Secades JJ, Lozano R, Cacabelos R (1999) Double-blind placebocontrolled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp Clin Pharmacol 21, 633-644.
100. Mosconi L, Rinne JO, Tsui WH, Berti V, Li Y, Wang H, Murray J, Scheinin N, Nagren K, Williams S, Glodzik L, De Santi S, Vallabhajosula S, de Leon MJ (2010) Increased fibrillar amyloid-beta burden in normal individuals with a family history of late-onset Alzheimer's. Proc Natl Acad Sci U S A 107, 5949-5954.
101. Giles RE, Blanc H, Cann HM, Wallace DC (1980) Maternal inheritance of human mitochondrial DNA. Proc Natl Acad Sci U S A 77, 6715-6719.
102. Brown WM, George M, Jr., Wilson AC (1979) Rapid evolution of animal mitochondrial DNA. Proc Natl Acad Sci U S A 76, 1967-1971.
103. Scheffler K, Krohn M, Dunkelmann T, Stenzel J, Miroux B, Ibrahim S, von Bohlen Und Halbach O, Heinze HJ, Walker LC, Gsponer JA, Pahnke J (2012) Mitochondrial DNA polymorphisms specifically modify cerebral beta-amyloid proteostasis. Acta Neuropathol 124, 199-208.
104. Khan SM, Cassarino DS, Abramova NN, Keeney PM, Borland MK, Trimmer PA, Krebs CT, Bennett JC, Parks JK, Swerdlow RH, Parker WD, Jr., Bennett JP, Jr. (2000) Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways. Ann Neurol 48, 148-155.
105. Silva DF, Santana I, Esteves AR, Baldeiras I, Arduino DM, Oliveira CR, Cardoso SM (2013) Prodromal metabolic phenotype in MCI cybrids: Implications for Alzheimer's disease. Curr Alzheimer Res 10, 180-190.
106. Tranah GJ, Yokoyama JS, Katzman SM, NallsM A, Newman AB, Harris TB, Cesari M, Manini TM, Schork NJ, Cummings SR, Liu Y, Yaffe K, Health A, Body Composition S (2014) Mitochondrial DNA sequence associations with dementia and amyloid-beta in elderly African Americans. Neurobiol Aging 35, 442 e441-448.
107. Coto E, Gomez J, Alonso B, Corao AI, Diaz M, Menendez M, Martinez C, Calatayud MT, Moris G, Alvarez V (2011) Late-onset Alzheimer's disease is associated with mitochondrial DNA 7028C/haplogroup H and D310 poly-C tract heteroplasmy. Neurogenetics 12, 345-346.
108. Hudson G, Sims R, Harold D, Chapman J, Hollingworth P, Gerrish A, Russo G, Hamshere M, Moskvina V, Jones N, Thomas C, Stretton A, Holmans PA, O'DonovanM C, Owen MJ, Williams J, Chinnery PF, Consortium G (2012) No consistent evidence for association between mtDNA variants and Alzheimer disease. Neurology 78, 1038-1042.
109. Santoro A, Balbi V, Balducci E, Pirazzini C, Rosini F, Tavano F, Achilli A, Siviero P, Minicuci N, Bellavista E, Mishto M, Salvioli S, Marchegiani F, Cardelli M, Olivieri F, Nacmias B, Chiamenti AM, Benussi L, Ghidoni R, Rose G, Gabelli C, Binetti G, Sorbi S, Crepaldi G, Passarino G, Torroni A, Franceschi C (2010) Evidence for sub-haplogroup h5 of mitochondrial DNA as a risk factor for late onset Alzheimer's disease. PLoS One 5, e12037.
110. Ridge PG, Maxwell TJ, Corcoran CD, Norton MC, Tschanz JT, O'Brien E, Kerber RA, Cawthon RM, Munger RG, Kauwe JS (2012) Mitochondrial genomic analysis of late onset Alzheimer's disease reveals protective haplogroups H6A1A/H6A1B: The Cache County Study on Memory in Aging. PLoS One 7, e45134.
111. Maruszak A, Safranow K, Branicki W, Gaweda-Walerych K, Pospiech E, Gabryelewicz T, Canter JA, Barcikowska M, Zekanowski C (2011) The impact of mitochondrial and nuclear DNA variants on late-onset Alzheimer's disease risk. J Alzheimers Dis 27, 197-210.
112. Ruiz-Pesini E, Mishmar D, Brandon M, Procaccio V, Wallace DC (2004) Effects of purifying and adaptive selection on regional variation in human mtDNA. Science 303, 223-226.
113. Mosconi L, de Leon M, Murray J, EL, Lu J, Javier E, McHugh P, Swerdlow RH (2011) Reduced mitochondria cytochrome oxidase activity in adult children of mothers with Alzheimer's disease. J Alzheimers Dis 27, 483-490.
114. Huang M, Graves LM (2003) De novo synthesis of pyrimidine nucleotides; emerging interfaces with signal transduction pathways. Cell Mol Life Sci 60, 321-336.